Switch to:
Also traded in: Australia, Germany, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt No Debt
MEOBF's Cash-to-Debt is ranked higher than
92% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. MEOBF: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
MEOBF' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.79
MEOBF's Equity-to-Asset is ranked higher than
67% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. MEOBF: 0.79 )
Ranked among companies with meaningful Equity-to-Asset only.
MEOBF' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.6  Med: 0.77 Max: 0.97
Current: 0.79
0.6
0.97
Piotroski F-Score: 1
Altman Z-Score: 0.82
Beneish M-Score: 10.69
WACC vs ROIC
14.65%
-16.30%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating Margin % -3740.21
MEOBF's Operating Margin % is ranked lower than
51% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. MEOBF: -3740.21 )
Ranked among companies with meaningful Operating Margin % only.
MEOBF' s Operating Margin % Range Over the Past 10 Years
Min: -3740.21  Med: -357.46 Max: 77.57
Current: -3740.21
-3740.21
77.57
Net Margin % -3192.59
MEOBF's Net Margin % is ranked higher than
68% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. MEOBF: -3192.59 )
Ranked among companies with meaningful Net Margin % only.
MEOBF' s Net Margin % Range Over the Past 10 Years
Min: -3192.59  Med: -404.99 Max: 74.96
Current: -3192.59
-3192.59
74.96
ROE % -14.71
MEOBF's ROE % is ranked higher than
76% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. MEOBF: -14.71 )
Ranked among companies with meaningful ROE % only.
MEOBF' s ROE % Range Over the Past 10 Years
Min: -51.29  Med: -14.65 Max: 32.19
Current: -14.71
-51.29
32.19
ROA % -11.46
MEOBF's ROA % is ranked higher than
76% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. MEOBF: -11.46 )
Ranked among companies with meaningful ROA % only.
MEOBF' s ROA % Range Over the Past 10 Years
Min: -48.74  Med: -10.62 Max: 22.31
Current: -11.46
-48.74
22.31
ROC (Joel Greenblatt) % -2716.73
MEOBF's ROC (Joel Greenblatt) % is ranked lower than
73% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. MEOBF: -2716.73 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
MEOBF' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -6085.79  Med: -3115.32 Max: 20767.8
Current: -2716.73
-6085.79
20767.8
3-Year Revenue Growth Rate -53.00
MEOBF's 3-Year Revenue Growth Rate is ranked higher than
58% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. MEOBF: -53.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
MEOBF' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -53  Med: -10 Max: 295.5
Current: -53
-53
295.5
3-Year EBITDA Growth Rate 7.30
MEOBF's 3-Year EBITDA Growth Rate is ranked higher than
62% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. MEOBF: 7.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
MEOBF' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -7.7  Med: 18.25 Max: 43.6
Current: 7.3
-7.7
43.6
3-Year EPS without NRI Growth Rate 0.50
MEOBF's 3-Year EPS without NRI Growth Rate is ranked lower than
94% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. MEOBF: 0.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
MEOBF' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -59.3  Med: 11.9 Max: 51.9
Current: 0.5
-59.3
51.9
GuruFocus has detected 3 Warning Signs with Mesoblast Ltd $MEOBF.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» MEOBF's 30-Y Financials

Financials (Next Earnings Date: 2017-11-15 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with MEOBF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 541711 
Compare:ASX:SPL, ASX:SRX, ASX:MVF, ASX:CUV, ASX:BNO, ASX:VLA, ASX:PNV, ASX:NEU, ASX:MDC, ASX:PYC, ASX:AHZ, ASX:ANR, ASX:CYP, ASX:MEB, ASX:ZLD, ASX:PRR, ASX:CGA, ASX:CPH, ASX:FTT, ASX:PAR » details
Traded in other countries:MSB.Australia, LWB.Germany, MESO.USA,
Headquarter Location:Australia
Mesoblast Ltd is engaged in the development of biologic products for the broad field of regenerative medicine. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells.

Mesoblast is developing adult stem cell therapies based on its proprietary mesenchymal precursor stem cell and culture-expanded mesenchymal stem cell technology platforms. It has nine clinical trial programs across four major areas (cardiovascular, spine disease, immunologic/inflammatory, and cancer) targeting chronic diseases affecting large populations.

Top Ranked Articles about Mesoblast Ltd

Mesoblast Outlines Potential Pathway to Accelerated Market Entry for MPC-150-IM in Advanced Chronic Heart Failure
Positive Trial Results of Mesoblast Cell Therapy in Post-Traumatic Osteoarthritis Published In Arthritis Research & Therapy
Mesoblast Rheumatoid Arthritis Trial Results Presented at EULAR Annual European Congress of Rheumatology
Successful Interim Analysis of Efficacy Endpoint in Mesoblast’s Phase 3 Trial for Chronic Heart Failure
Mesoblast Receives A$3.7 Million From the Australian Government for Research and Development Activities
FDA Clears Heart Disease Trial at Harvard's Boston Children’s Hospital Using Mesoblast's Cell Therapy to Grow Heart Muscle in Children With Congenital Heart Disease
Independent Data Monitoring Committee Initiates process for Interim Analysis of Mesoblast’s Phase 3 Chronic Heart Failure Trial
Mesoblast Raises US$40 Million

NEW YORK and MELBOURNE, Australia, March 27, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO) (ASX:MSB) today announced it has successfully completed a fully underwritten institutional placement of 26.25 million new shares (approx. 6% of issued capital) and has raised approx. US$40 million.  The placement price of A$2.00 per share represents a 4.8% discount to the 15 day VWAP of A$2.10.
Existing global institutional investors, together with new institutional and sophisticated investors, have strongly supported and participated in the placement. The proceeds will be used for Mesoblast’s ongoing Phase 3 clinical programs including chronic heart failure, as well as for manufacturing requirements associated with product commercialization.  The Company expects to report during CY2017 multiple clinical and regulatory outcomes related to its Tier 1 product candidates, which may facilitate strategic alliances with partners who share our corporate vision. Bell Potter Securities Limited acted as Lead Manager and Underwriter to the placement. The shares have not been and will not be registered under the US Securities Act of 1933, as amended (US Securities Act) or the securities laws of any state or other jurisdiction of the United States. They may not be offered or sold, directly or indirectly, in the United States or to, or for the account or benefit of, any US Person (as such term is defined in Regulation S of the US Securities Act), unless an exemption from such registration applies. Any offer, sale or resale of the shares within the United States by any dealer (whether or not participating in the offer) may violate the registration requirements of the US Securities Act if made prior to 40 days after the completion of the offer or if purchased by a dealer in the offer. This announcement does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of, any US Person. About Mesoblast
Mesoblast Limited (NASDAQ:MESO) (ASX:MSB) is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast’s allogeneic, ‘off-the-shelf’ cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular diseases, immune-mediated and inflammatory disorders, orthopedic disorders, and oncologic/hematologic conditions. Forward-Looking Statements
This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast's actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.
For further information, please contact:

Julie Meldrum
Corporate Communications
Mesoblast
T: 61 3 9639 6036
E: [email protected]

Schond Greenway
Investor Relations
Mesoblast
T: 1 212 880 2060
E: [email protected]

Read more...
Durable Three-Year Outcomes In Degenerative Disc Disease After a Single Injection of Mesoblast’s Cell Therapy

MELBOURNE, Australia and NEW YORK, March 15, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO) (ASX:MSB) today announced 36-month results from the randomized, placebo-controlled 100-patient Phase 2 trial of its proprietary allogeneic Mesenchymal Precursor Cells (MPCs) in patients with chronic low back pain (CLBP) due to intervertebral disc degeneration.  A single intra-discal injection of 6 million MPCs resulted in meaningful improvements in both pain and function that were durable for at least 36 months.  
“The sustained benefits on pain and function over three years seen with a single injection of Mesoblast’s cell therapy have the potential to transform the treatment paradigm for chronic low back pain due to disc degeneration,” said trial investigator Dr Hyun Bae, Professor of Surgery and Director of Education at the Cedars Sinai Spine Center, and Director of the Spine Institute in Los Angeles, CA.  â€œInstead of replacing or fusing the disc, there is mounting compelling evidence that we can use this regenerative medicine to heal the disc.  We are fast approaching this inflection point in the treatment of low back pain, which is particularly important in view of the epidemic of opioid abuse." The durable outcomes seen from a single MPC injection in patients with degenerative disc disease who have failed conservative measures are consistent with an overarching mechanism of action that may also be evident in treatment of other chronic diseases where a single MPC dose has resulted in sustained benefits, including advanced chronic heart failure and biological-resistant rheumatoid arthritis.  In each of these diseases, MPCs are thought to be activated by signals in the damaged tissues to release factors that both inhibit damaging inflammation and induce a pro-reparative state. The Phase 2 trial compared a single intra-discal injection of 6 million or 18 million MPCs against two placebo arms, saline or hyaluronic acid, using a pre-specified Per Protocol (PP) population analysis.  The primary endpoint composite was the same as is being used in the ongoing Phase 3 trial, a 50% reduction in the Visual Analog Scale (VAS) pain score and a 15-point reduction in the Oswestry disability index (ODI), with no additional intervention, at both 12 and 24 months. In line with United States Food and Drug Administration (FDA) guidance for the ongoing Phase 3 trial, the 24-month primary endpoint composite was additionally analyzed using an intent to treat (ITT) population.  The 36-month analysis aimed to determine the proportion of patients who maintained treatment success beyond the 24-month primary evaluation. Key trial results were: the primary endpoint composite over 24 months was achieved by 41% of patients who received 6 million MPCs, 35% of the 18 million MPC group, 18% of the hyaluronic acid group, and 13% of the saline group, using the pre-specified PP population analysis
-  pain responder criteria (50% pain reduction with no additional intervention at both 12 and 24 months) was achieved by 52% of the 6 million MPC group compared with 13% of the saline group (p<0.05)
-  functional responder criteria (15-point reduction in ODI and no additional intervention at both 12 and 24 months) was achieved by 48% of the 6 million MPC group compared with 13% of the saline group (p<0.05)similar results were seen for the primary endpoint composite over 24 months using the ITT analysis, with 38% of the 6 million MPC group achieving this outcome compared with 10% of the saline group (p<0.05)
-  82% of the 6 million MPC group who achieved the primary endpoint composite over 24 months maintained treatment success using this composite endpoint at 36 months
-  86% of the 6 million MPC group who successfully met the pain responder criteria (50% pain reduction with no additional intervention at both 12 and 24 months) remained pain responders through 36 months
-  92% of the 6 million MPC group who met the functional responder criteria (15-point reduction in ODI and no additional intervention at both 12 and 24 months) remained functional responders through 36 monthsthere were no significant differences in measurements of safety between cell-treated patients and controls over 36 months The 36-month Phase 2 trial results support the ongoing 360-patient Phase 3 trial of Mesoblast's product candidate MPC-06-ID for CLBP by reinforcing the rationale for MPC dose selection, use of saline control, and the trial's primary endpoint composite over 24 months.  If similar clinical durability is seen in the Phase 3 program, it is anticipated such data will translate into meaningful health economic benefits including increased productivity that may support attractive product reimbursement. In December 2016, Mesoblast and Mallinckrodt Pharmaceuticals entered into an agreement to exclusively negotiate a commercial and development partnership for MPC-06-ID in the treatment of chronic low back pain due to disc degeneration. About Chronic Low Back Pain (CLBP) Caused By Degenerative Disc Disease Over 33 million1 patients in the U.S. alone suffer from CLBP with approximately 22%2 caused by degenerative disc disease.  Total costs of low back pain in the U.S. are estimated to be between US$100 billion and US$200 billion annually with two thirds of these costs attributed to patients’ decreased wages and productivity. All therapies for progressive, severe and debilitating pain due to degenerating intervertebral discs treat the symptoms of the disease, but are not disease-modifying and thus do not address the underlying cause of the disease. Limited treatment options exist for patients who have failed conservative treatment (e.g. physical therapy, anti-inflammatory agents or analgesics) or other measures including opioids and epidural steroid injections.  When disc degeneration has progressed to a point that pain and loss of function can no longer be managed by conservative means, major invasive surgery is the only remaining option.  Even with surgical intervention such as spinal fusion or artificial disc replacement, over 50% of patients are considered treatment failures. Mesoblast’s MPC-06-ID Phase 3 program targets a patient population with significant unmet need who have exhausted conservative treatment options.  MPC-06-ID is being developed to alleviate pain and improve function, either before the use of opioids and/or epidural steroid injections or after failure of these approaches, in order to prevent invasive and costly surgical interventions. About Mesoblast
Mesoblast Limited (NASDAQ:MESO) (ASX:MSB) is a global leader in developing innovative cell-based medicines.  The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates.  Mesoblast’s allogeneic, ‘off-the-shelf’ cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions. Forward-Looking Statements
This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.  We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws.  Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse.  You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website.  Uncertainties and risks that may cause Mesoblast's actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements.  We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise. 1 Decision Resource 2015 Chronic Pain Report
2 https://academic.oup.com/painmedicine/article-lookup/doi/10.1111/pme.12809
For further information, please contact:
                                   
Julie Meldrum
Corporate Communications
T: 61 3 9639 6036
E: [email protected]

Schond Greenway
Investor Relations
T: 1 212 880 2060
E: [email protected]

Read more...
FDA Grants Fast Track Designation for Mesoblast’s Cell Therapy in Children With Acute Graft Versus Host Disease

NEW YORK and MELBOURNE, Australia, March 07, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO) (ASX:MSB) today announced that the United States Food and Drug Administration (FDA) has granted a Fast Track designation for the use of its cell therapy, MSC-100-IV, to achieve improved overall response rate in children with steroid refractory acute Graft Versus Host Disease (aGVHD). Fast Track designation has the potential to shorten the time to FDA approval of MSC-100-IV for this indication through priority review (shortened FDA review process from 10 to 6 months) and a streamlined rolling review process (completed sections of the Biologics License Application, BLA, can be submitted for FDA review as they become available, instead of waiting for all to be completed). The product candidate's existing Orphan Indication designation may additionally lead to potential commercial benefits following FDA approval. Mesoblast’s application for Fast Track status was supported by the clinical data in 241 pediatric patients with steroid refractory aGVHD who were treated on a single expanded access protocol (EAP) with MSC-100-IV. Overall response rate at Day 28 in this group was 65%, and day 100 survival was significantly improved in children who achieved an overall response at day 28 (82% vs. 39%, log rank p-value <0.0001). The clinical results from the EAP were also used by Mesoblast in earlier discussions with the FDA that initially established the current accelerated development pathway for MSC-100-IV as front-line therapy in children with steroid-refractory aGVHD. Based on these discussions, Mesoblast believes that a single successful open-label Phase 3 trial will be sufficient for conditional FDA approval. In November 2016, Mesoblast reported that the ongoing 60-patient open label Phase 3 registration trial of MSC-100-IV in children with steroid refractory aGVHD was successful in a pre-specified interim futility analysis using the trial’s primary endpoint of Day 28 overall responses. The futility threshold was established using a Bayesian analysis method which determined the likelihood of obtaining a statistically significant treatment effect at study completion based on the data observed at this interim time point. Enrollment in this Phase 3 trial is expected to complete mid-2017 with a top-line read out in 2H CY 2017. In December 2016, Mesoblast entered into exclusive negotiations with Mallinckrodt Pharmaceuticals for a commercial and development partnership to develop product candidates for pediatric and adult aGVHD, outside of Japan and China.  MSC-100-IV is marketed as TEMCELL HS Inj.® for acute GVHD in children and adults in Japan by Mesoblast’s licensee, JCR Pharmaceuticals. About Mesoblast
Mesoblast Limited (NASDAQ:MESO) (ASX:MSB) is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast’s allogeneic, ‘off-the-shelf’ cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular diseases, immune-mediated and inflammatory disorders, orthopedic disorders, and oncologic/hematologic conditions. Forward-Looking Statements
This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast's actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.
For further information, please contact:

Julie Meldrum
Corporate Communications
Mesoblast
T: 61 3 9639 6036
E: [email protected]

Schond Greenway
Investor Relations
Mesoblast
T: 1 212 880 2060
E: [email protected]

Read more...

Ratios

vs
industry
vs
history
PB Ratio 0.87
MEOBF's PB Ratio is ranked higher than
88% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. MEOBF: 0.87 )
Ranked among companies with meaningful PB Ratio only.
MEOBF' s PB Ratio Range Over the Past 10 Years
Min: 0.56  Med: 1.01 Max: 2.22
Current: 0.87
0.56
2.22
PS Ratio 172.50
MEOBF's PS Ratio is ranked lower than
62% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. MEOBF: 172.50 )
Ranked among companies with meaningful PS Ratio only.
MEOBF' s PS Ratio Range Over the Past 10 Years
Min: 6.67  Med: 31.29 Max: 266.25
Current: 172.5
6.67
266.25
EV-to-EBIT -4.46
MEOBF's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. MEOBF: -4.46 )
Ranked among companies with meaningful EV-to-EBIT only.
MEOBF' s EV-to-EBIT Range Over the Past 10 Years
Min: -46.2  Med: -7.15 Max: -2.5
Current: -4.46
-46.2
-2.5
EV-to-EBITDA -4.54
MEOBF's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. MEOBF: -4.54 )
Ranked among companies with meaningful EV-to-EBITDA only.
MEOBF' s EV-to-EBITDA Range Over the Past 10 Years
Min: -46.2  Med: -7.25 Max: -2.5
Current: -4.54
-46.2
-2.5
EV-to-Revenue 167.01
MEOBF's EV-to-Revenue is ranked lower than
61% of the 716 Companies
in the Global Biotechnology industry.

( Industry Median: 13.06 vs. MEOBF: 167.01 )
Ranked among companies with meaningful EV-to-Revenue only.
MEOBF' s EV-to-Revenue Range Over the Past 10 Years
Min: 5  Med: 29.6 Max: 266.4
Current: 167.01
5
266.4
Current Ratio 1.73
MEOBF's Current Ratio is ranked lower than
61% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. MEOBF: 1.73 )
Ranked among companies with meaningful Current Ratio only.
MEOBF' s Current Ratio Range Over the Past 10 Years
Min: 1.73  Med: 6.56 Max: 21.2
Current: 1.73
1.73
21.2
Quick Ratio 1.73
MEOBF's Quick Ratio is ranked lower than
58% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. MEOBF: 1.73 )
Ranked among companies with meaningful Quick Ratio only.
MEOBF' s Quick Ratio Range Over the Past 10 Years
Min: 1.73  Med: 6.56 Max: 21.2
Current: 1.73
1.73
21.2
Days Sales Outstanding 71.50
MEOBF's Days Sales Outstanding is ranked higher than
88% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. MEOBF: 71.50 )
Ranked among companies with meaningful Days Sales Outstanding only.
MEOBF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.07  Med: 3.23 Max: 71.73
Current: 71.5
0.07
71.73

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -10.90
MEOBF's 3-Year Average Share Buyback Ratio is ranked higher than
59% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. MEOBF: -10.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MEOBF' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -28  Med: -13.1 Max: -5.3
Current: -10.9
-28
-5.3

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 4.86
MEOBF's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
99.99% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 3.53 vs. MEOBF: 4.86 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
MEOBF' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0  Med: 0 Max: 4.86
Current: 4.86
0
4.86
Price-to-Median-PS-Value 5.63
MEOBF's Price-to-Median-PS-Value is ranked higher than
60% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. MEOBF: 5.63 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MEOBF' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.22  Med: 2.38 Max: 8.24
Current: 5.63
0.22
8.24
Earnings Yield (Greenblatt) % -22.42
MEOBF's Earnings Yield (Greenblatt) % is ranked lower than
64% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. MEOBF: -22.42 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MEOBF' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -40.4  Med: -13.95 Max: -2.2
Current: -22.42
-40.4
-2.2

More Statistics

Revenue (TTM) (Mil) $2.41
EPS (TTM) $ -0.19
Beta2.94
Short Percentage of Float0.00%
52-Week Range $0.81 - 2.39
Shares Outstanding (Mil)432.56

Analyst Estimate

Jun18 Jun19 Jun20
Revenue (Mil $) 8 29 472
EPS ($) -0.19 -0.11 0.60
EPS without NRI ($) -0.19 -0.11 0.60
EPS Growth Rate
(Future 3Y To 5Y Estimate)
24.00%
Dividends per Share ($)
» More Articles for MEOBF

Headlines

Articles On GuruFocus.com
Mesoblast Outlines Potential Pathway to Accelerated Market Entry for MPC-150-IM in Advanced Chronic Aug 23 2017 
Positive Trial Results of Mesoblast Cell Therapy in Post-Traumatic Osteoarthritis Published In Arthr Aug 16 2017 
Mesoblast Rheumatoid Arthritis Trial Results Presented at EULAR Annual European Congress of Rheumato Jun 22 2017 
Successful Interim Analysis of Efficacy Endpoint in Mesoblast’s Phase 3 Trial for Chronic Heart Apr 10 2017 
Mesoblast Receives A$3.7 Million From the Australian Government for Research and Development Activit Apr 06 2017 
FDA Clears Heart Disease Trial at Harvard's Boston Children’s Hospital Using Mesoblast's Cell T Apr 03 2017 
Independent Data Monitoring Committee Initiates process for Interim Analysis of Mesoblast’s Mar 31 2017 
Mesoblast Raises US$40 Million Mar 27 2017 
Durable Three-Year Outcomes In Degenerative Disc Disease After a Single Injection of Mesoblast Mar 15 2017 
FDA Grants Fast Track Designation for Mesoblast’s Cell Therapy in Children With Acute Graft Ve Mar 07 2017 

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}